Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$470.08 USD

470.08
1,446,023

+0.27 (0.06%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $470.60 +0.52 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (148 out of 244)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Zacks Investment Ideas feature highlights: Intuitive Surgical, SharkNinja and DaVita

by Zacks Equity Research

Intuitive Surgical, SharkNinja and DaVita have been highlighted in this Investment Ideas article.

Urmimala Biswas headshot

3 Medical Instruments Industry Stocks to Buy on genAI and M&A Boost

by Urmimala Biswas

ISRG, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar the prospects.

Derek Lewis headshot

3 Red Hot Stocks Flashing Buy Signals: DVA, ISRG, SN

by Derek Lewis

Stocks making new highs tend to make even higher highs, particularly when positive earnings estimate revisions hit the tape. And that's precisely what these three companies have seen.

Zacks Equity Research

CVS Stock Gains From Its Birth Control Prescribing Service Launch

by Zacks Equity Research

CVS Health announces that nearly 400 CVS Pharmacy locations in Massachusetts have started offering hormonal contraceptive prescribing services.

Zacks Equity Research

Reasons to Retain Inari Medical Stock in Your Portfolio for Now

by Zacks Equity Research

NARI continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.

Zacks Equity Research

Roche Stock to Benefit From Accu-Chek Smartguide Launch in Europe

by Zacks Equity Research

RHHBY's Accu-Chek Smartguide will provide several predictive features aimed at enhancing patient safety. However, the device may face tough competition from existing CGM devices.

Zacks Equity Research

Labcorp Stock Gains From Market Expansion Efforts Amid Macro Woes

by Zacks Equity Research

LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.

Zacks Equity Research

Sanara Stock Gains From New US Distribution Deal With ChemoMouthPiece

by Zacks Equity Research

SMTI, along with InfuSystem, inked a U.S. distribution agreement with ChemoMouthpiece. Under the agreement, ChemoMouthpiece's oral cryotherapy device will be distributed in cancer centers.

Zacks Equity Research

Intuitive Surgical, Inc. (ISRG) Rises Higher Than Market: Key Facts

by Zacks Equity Research

Intuitive Surgical, Inc. (ISRG) concluded the recent trading session at $490.93, signifying a +1.38% move from its prior day's close.

Zacks Equity Research

Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Intuitive Surgical (ISRG) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Equity Research

The Zacks Rank Explained: How to Find Strong Buy Medical Stocks

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.

Zacks Equity Research

Paragon 28 Stock Gains From the Latest Launch of Its Right-Angle Drill

by Zacks Equity Research

FNA launched the Right-Angle Drill to enhance the APEX 3D Total Ankle Replacement System. The drill is designed to improve tibia preparation.

Zacks Equity Research

Reasons to Retain ResMed Stock in Your Portfolio for Now

by Zacks Equity Research

Strong demand for RMD's market-leading mask portfolio raises investors' optimism.

Zacks Equity Research

The Zacks Analyst Blog Highlights Prosus, Intuitive Surgical and Unilever

by Zacks Equity Research

Prosus, Intuitive Surgical and Unilever are included in this Analyst Blog.

John Blank headshot

August U.S. CPI Data: Global Week Ahead

by John Blank

Investors are on edge -- ahead of more key macro events -- that could shape the tone for trading in the weeks ahead.

Zacks Equity Research

Will Trinity Biotech Stock Gain From Its Latest Patent Process?

by Zacks Equity Research

TRIB announces updates on its European patented process. The company aims to use this process to improve the functionality of its glucose biosensor in its next-gen CGM technology.

Tracey Ryniec headshot

5 Top Red-Hot Stocks to Buy Now

by Tracey Ryniec

he hottest stocks might not be those you think. Look past AI and technology stocks.

Zacks Equity Research

Here's Why Universal Health Shares are Attracting Investors Now

by Zacks Equity Research

UHS remains well-poised for growth on improved patient days at its behavioral healthcare facilities, acquisitions and solid cash flows.

Zacks Equity Research

PBH Stock Might Get a Boost From Focused Brand-Building Efforts

by Zacks Equity Research

Prestige Consumer puts emphasis on brand building and product innovation in niche consumer healthcare categories to improve the lives of its consumers.

Zacks Equity Research

Will Paragon 28 Stock Gain From the Latest Product Launch of R3FLEX?

by Zacks Equity Research

FNA recently introduced the R3FLEX Stabilization System, whose design should allow surgeons to restore a patient's soft tissue to a more natural anatomy.

Zacks Equity Research

Align Technology Stock Dips on Macroeconomic Issues, FX Headwind

by Zacks Equity Research

ALGN is facing a decline in Invisalign ASPs for comprehensive treatment options. This is resulting in a decline in the company's revenues.

Zacks Equity Research

Abbott's Lingo CGM System Gains U.S. Availability: Stock to Gain?

by Zacks Equity Research

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who are not on insulin.

Zacks Equity Research

Intuitive Surgical, Inc. (ISRG) Sees a More Significant Dip Than Broader Market: Some Facts to Know

by Zacks Equity Research

In the most recent trading session, Intuitive Surgical, Inc. (ISRG) closed at $476.69, indicating a -1.05% shift from the previous trading day.

Zacks Equity Research

Intuitive Surgical Gains 40.5% Year to Date: What's Driving the Stock?

by Zacks Equity Research

ISRG's shares gain on the back of strength in da Vinci surgical system.

Zacks Equity Research

QIAGEN Stock Likely to Gain on Collaboration for APOE Genotyping

by Zacks Equity Research

QGEN collaborates with Eli Lilly to develop a QIAstat-Dx IVD panel for APOE genotyping.